1Morschhauser F, Cayuela JM, Martini S, et al. Evaluation of minimal residual disease using reverse-transcription polymerase chain reaction in t(8;21 ) acute myeloid leukemia: a multicenter study of 51 patient. J Clin Oncol, 2000,18: 788-794.
2Gallego M, Carroll A J, Gad GS, et al. Variant t ( 8 ;21 ) rearrangements in acute myeloblastic leukemia of childhood. Cancer Genet Cytogenet,1994,75: 139-144.
3deTh H, ChomienneC, LanotteM, etal. Thet(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor a gene to a novel transcribed locus. Nature, 1990, 347: 558-561.
4Jurcic JG, Nimer SD, Scheinberg DA, et al. Prognostic significance of minimal residual disease detection and PML/RAR-a isoform type:long term follow-up in acute promyelocytic leukemia. Blood, 2001,98: 2651-2656.
5de Botton S, Chevret S, Sanz M, et al. Additional chromosomal abnormalities in patients with acute promyelocytic leukemia (APL) do not confer poor prognosis: results of APL 93 trial. Br J Haematol,2000, 111: 801-806.
6Licht JD, Chomienne C, Goy A, et al. Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation t( 11 ;17). Blood, 1995, 85: 1083-1094.
8Wells RA, Catzavelos C, Kamel-Reid S. Fusion of retinoic acid receptor alpha to NuMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocytic leukemia. Nature Genet,1997,17: 109-113.
9Arnould C, Philippe C, Bourdon V, et al. The signal transducer and activator of transcription STAT5b gene is a new partner of retinoic acid receptor alpha in acute promyelocyticlike leukemia. Hum Mol Genet,1999, 8: 1741-1749.
10Marlton P, Keating M, Kantarjian H, et al. Cytogenetic and clinical correlates in AML patients with abnormalities of chromosome 16.Leukemia,1995,9: 965-971.
